Hypereosinophilic syndrome masquerading as acrodermatitis enteropathica
Sir, Hypereosinophilic syndrome most commonly involves the heart, central nervous system, lungs and the skin. Gastrointestinal tract involvement is very rare. We report a case that presented with skin manifestations of acquired acrodermatitis enteropathica secondary to hypereosinophilic syndrome of the gastrointestinal tract.
A 36-year-old unmarried gentleman presented to Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India with multiple episodes of erosive desquamating plaques all over the body, particularly on the flexures and extremities, with intense itching and chronic diarrhea for the last 10 years. On examination, he was short (height: 140 cm), had sparse hair in the axillary, pubic, beard and mustache area but testis and scrotum were normal. He had generalized xerosis, erosive desquamating plaques on the trunk and extremities, predominantly on the flexures, with sparing of the face, palms and soles [ Figure 1a -c]. He also had angular cheilitis, perianal depigmentation with mild erythema, and inguinal and cervical lymphadenopathy.
His routine blood investigations revealed anemia (hemoglobin: 8 g/dl), thrombocytosis (platelet: 789,000 cells/cu.mm), leukocytosis (16,300 cells/ cu.mm), eosinophilia (2867/cu.mm) and increased lactate dehydrogenase. The serum zinc level was 29 µg/ dl (normal: 70-125 µg/dl), and serum alkaline phosphatase was 122 IU/l (normal: 30-140 IU/l). Histopathology of skin lesion showed hyperkeratosis, subcorneal vesicles, acanthosis, spongiosis and perivascular and peri-appendageal inflammatory infiltrate composed of lymphocytes, neutrophils and some eosinophils, consistent with psoriasiform dermatitis [ Figure 2 ]. In view of the clinical picture, hypozincemia and histologic changes, diagnosis of acquired acrodermatitis enteropathica was made, and the patient was started on oral zinc 3 mg/kg/day and emollients, but there was no improvement of the skin symptoms even after 1 month. At the same time, the patient was being investigated for diarrhea and anemia; his bone marrow biopsy revealed marrow hyperplasia with increased eosinophilic precursors. His colonic biopsy revealed eosinophilic colitis (eosinophil count >25 per high power field) [ Figure 3 ] and esophageal biopsy was reported to be eosinophilic esophagitis (eosinophil count >7 per high power field) [ Figure 4 ]. Fine-needle aspiration cytology of lymph nodes showed reactive lymphadenitis. Repeat absolute eosinophil count done at this point was 3456/cu.mm, after 8 months of initial investigation. His serum immunoglobulin E level was found to be increased (5478 IU/ml). Hence, the final diagnosis was revised to hypereosinophilic syndrome.
Investigations to screen other system involvement such as echocardiography, magnetic resonance imaging brain, computed tomography chest were all normal. Serum B12 level was normal (239 pg/ml). Viral markers (hepatitis B, C, HIV) and rheumatoid factor were negative. Investigations to rule out secondary causes of eosinophilia such as stool for ova-cyst, blood culture for bacteria, antinuclear antibodies, C-antineutrophil cytoplasmic antibody and P-antineutrophil cytoplasmic antibody were negative. Serum tryptase and interleukin-5 levels were not done because of lack of facilities. The patient was then started on oral prednisolone 1 mg/kg/day in addition to zinc acetate 3 mg/kg/day and showed dramatic clinical improvement within a month [ Figure 5a -c]. His absolute eosinophil count after 2 months of systemic steroids decreased to 130/mm 3 and the steroid was then gradually tapered.
Hypereosinophilic syndrome was first described in 1968, by Hardy and Anderson. It manifests with varied clinical presentation and so, is essentially a diagnosis of exclusion. The revised diagnostic criteria of hypereosinophilic syndrome are:
1.
Blood eosinophilia >1500 eosinophils/mm 3 on at least two separate determinations or evidence of prominent tissue eosinophilia associated with symptoms and marked blood eosinophilia.
2.
Exclusion of secondary causes of eosinophilia such as parasitic or viral infections, allergic diseases, drug or chemical-induced eosinophilia, hypoadrenalism and neoplasms. 1 The tissues most vulnerable and most frequently affected by eosinophils in decreasing order of frequency are the heart (~60%), skin, nervous system, respiratory and gastrointestinal tract (~20%).
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There are three forms of the disease: myeloproliferative, lymphocytic and familial. Myeloproliferative form associated with FIP1L1-PDGFRA mutation is more common in men. This usually presents with fever, weight loss, fatigue, malaise, skin lesions and hepatosplenomegaly and responds to imatinib. Cardiac disease is more frequent, and the patient usually dies within 2 years of presentation. Serum B12 levels and tryptase may be raised in the myeloproliferative form of hypereosinophilic syndrome. In our patient, serum B12 was normal and tryptase was not done. Lymphocytic form presents with pruritus, eczema, erythroderma, urticaria, angioedema and lymphadenopathy. Lymphocytic hypereosinophilic syndrome follows a more benign course. 3 There is often a raised serum immunoglobulin E level. Our patient had similar clinical feature and fits into this form of hypereosinophilic syndrome.
Eosinophilic gastroenteritis affects the entire gastrointestinal tract. 4 It is diagnosed by the presenting gastrointestinal symptoms, pathological eosinophilic infiltration of the gastrointestinal tract, no eosinophilic involvement of organs outside the gastrointestinal tract and no parasite infestation. 4 Abdominal pain and diarrhea with malabsorption have been described, explaining the underlying zinc deficiency in our case.
In hypereosinophilic syndrome, eosinophil count tends to fluctuate with the interleukin-5 levels and the symptoms worsen or get better depending on the eosinophil count. Our patient had an increase in absolute eosinophil count on the second occasion and there was corresponding worsening of the skin manifestations. Treatment includes systemic glucocorticoid 0.5-1 mg/ kg/day, which is effective in reducing the eosinophil count, and antineoplastic drugs (cyclophosphamide, vincristine, cytarabine, etoposide) for slowing eosinophil production.
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Acquired zinc deficiency has been reported in numerous conditions such as anorexia nervosa, alcoholism, inflammatory bowel disease, blind loop syndromes and total parenteral nutrition. Our patient had zinc deficiency secondary to eosinophilic gastroenteritis. Chronic zinc deficiency leads to growth retardation and hypogonadism which is evident in our case.
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Sir, Adalimumab is the first recombinant human IgG1 antibody that binds specifically to tumor necrosis factor alpha, and blocks its interaction with tumor necrosis factor receptors on the cell surface. It is often used, in the field of dermatology, to treat psoriasis, and it has recently shown efficacy in both therapy-resistant hidradenitis suppurativa, as well as pyoderma gangrenosum. Of late, reports of paradoxical skin reactions have increased, since the drug is currently being used in an increasing number of indications, including pyoderma gangrenosum.
A 50-year-old male, diagnosed with hidradenitis suppurativa [ Figure 1 ] 5 years ago, was started on subcutaneous injections of adalimumab, every 2 weeks. After three subcutaneous doses (160, 80 and 40 mg, respectively), he developed multiple, painful skin papules over his lower limbs, which rapidly progressed into ulcers [ Figure 2 ]. He denied any history off ever, systemic symptoms, trauma or taking any additional drugs. Physical examination revealed a few, well-circumscribed, round erythematous to violaceous plaques, with ulcerated or crusted necrotic centers. Laboratory examinations showed elevated white blood cell count (11.780/μL) and C-reactive protein level (2.4 mg/mL). The patient was admitted with a clinical suspicion of drug-induced vasculitis or pyoderma gangrenosum, and he was administered intravenous methylprednisolone (40mg/12h, at 1mg/kg/day), amoxicillin/clavulanic acid (as bacterial super infection of the ulcerated lesions was suspected), and adalimumab was withdrawn. Within a few days of admission, the cutaneous lesions rapidly improved, developed crusting and diminished in both size and number. The serologic profile and autoimmune blood tests were negative. Chest skiagram was unremarkable. Abdominal ultrasound detected hepatic steatosis. Colonoscopy did not reveal signs suggestive of inflammatory bowel disease. Histopathological examination was compatible with neutrophilic dermatitis [ Figures 3 and 4 ]. Direct immunofluorescence, bacterial, mycobacterial and fungal cultures from skin biopsy specimen were negative. The patient was diagnosed with adalimumab-induced pyoderma gangrenosum. He was given systemic corticosteroids, following which his lesions resolved dramatically, and he was discharged in 6 days.
As anti-tumor necrosis factor therapy is being used widely to treat inflammatory Bowen's disease, rheumatologic diseases and even psoriasis, paradoxical reactions are increasingly being reported. These reactions are either idiosyncratic new-onset lesions, or an exacerbation of a condition that is normally improved by the same anti-tumor necrosis factor agent. 1 These are hard to avoid and predict. Psoriasis seems to be the paradigm of cutaneous reactions, but there are recent reports of pyoderma gangrenosum [ Table 1 ], hidradenitis suppurativa, vitiligo, sarcoidosis and SAPHO syndrome developing as a result of this class of drugs, thus
